In addition to this, upon doxorubicin-induced NF-κB activation, this transcription factor may no longer remain stably bound to κB elements in vivo; thus, suggesting that doxorubicin-induced NF-κB activation may not necessarily contribute to the anti-apoptotic activity in cancer cells [45]. The gene discussed is NFKB1; the disease is cancer.